May 10 (Reuters) - Novavax Inc said on Monday its combined flu and COVID-19 vaccine produced functional antibodies against influenza and the coronavirus in a preclinical study. (https://refini.tv/3bg25TM) (Reporting by Mrinalika Roy in Bengaluru; Editing by Amy Caren Daniel)
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
19.56 USD | -6.75% | +28.23% | +307.40% |
06/06 | S&P 500, Nasdaq dip on the eve of US payrolls data | RE |
06/06 | Wall Street mixed as Nvidia retreat hits tech stocks; payrolls data in focus | RE |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+307.40% | 2.94B | |
+55.55% | 59.34B | |
+43.17% | 40.24B | |
-4.71% | 39.88B | |
-5.56% | 28.55B | |
+13.76% | 27.26B | |
-22.00% | 19.23B | |
+31.50% | 12.61B | |
+2.16% | 12.49B | |
+25.70% | 12.28B |
- Stock Market
- Equities
- NVAX Stock
- News Novavax, Inc.
- Novavax : combined influenza/COVID-19 vaccine shows promise in preclinical study